182
Participants
Start Date
January 31, 2008
Primary Completion Date
August 31, 2008
Study Completion Date
August 31, 2008
insulin degludec/insulin aspart
Formulation B: Treat-to-target dose titration scheme, injection s.c., twice daily
insulin degludec/insulin aspart
Formulation B: Treat-to-target dose titration scheme, injection s.c., twice daily
biphasic insulin aspart
Treat-to-target dose titration scheme, injection s.c., twice daily
metformin
Tablets, 1500-2000 mg/daily
Novo Nordisk Investigational Site, Berlin
Novo Nordisk Investigational Site, Lahti
Novo Nordisk Investigational Site, La Rochelle
Novo Nordisk Investigational Site, Granada
Novo Nordisk Investigational Site, Madrid
Novo Nordisk Investigational Site, Grenoble
Novo Nordisk Investigational Site, Bar-le-Duc
Novo Nordisk Investigational Site, Hayange
Novo Nordisk Investigational Site, Nevers
Novo Nordisk Investigational Site, Saarbrücken
Novo Nordisk Investigational Site, Völklingen
Novo Nordisk Investigational Site, Saint Ingbert
Novo Nordisk Investigational Site, Kuopio
Novo Nordisk Investigational Site, Wangen
Novo Nordisk Investigational Site, Nanterre
Novo Nordisk Investigational Site, Pointe à Pitre
Novo Nordisk Investigational Site, Helsinki
Novo Nordisk Investigational Site, Pori
Novo Nordisk Investigational Site, Pirna
Novo Nordisk Investigational Site, Riesa
Novo Nordisk Investigational Site, Bydgoszcz
Novo Nordisk Investigational Site, Gniewkowo
Novo Nordisk Investigational Site, Nysa
Novo Nordisk Investigational Site, Płock
Novo Nordisk Investigational Site, Szczecin
Novo Nordisk Investigational Site, Tychy
Novo Nordisk Investigational Site, Warsaw
Novo Nordisk Investigational Site, Wroclaw
Novo Nordisk Investigational Site, Almería
Novo Nordisk Investigational Site, Barcelona
Novo Nordisk Investigational Site, San Juan
Lead Sponsor
Novo Nordisk A/S
INDUSTRY